Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 9
Submit an article Journal homepage
2,591
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Involved free light chain: an early independent predictor of response and progression in multiple myeloma

Charlotte Grana Department of Medicine, Karolinska Institutet, Stockholm, Sweden;b Department of Clinical Chemistry, Karolinska University Laboratory, Stockholm, SwedenCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6069-6615View further author information
ORCID Icon,
Gabriel Aframa Department of Medicine, Karolinska Institutet, Stockholm, Sweden;c Haematology Center, Karolinska University Hospital, Stockholm, SwedenView further author information
,
Johan Liwinga Department of Medicine, Karolinska Institutet, Stockholm, SwedenView further author information
,
Andre Verhoekd Ingress-Health Nederland BV, Rotterdam, The NetherlandsView further author information
&
Hareth Nahia Department of Medicine, Karolinska Institutet, Stockholm, Sweden;c Haematology Center, Karolinska University Hospital, Stockholm, SwedenView further author information
Pages 2227-2234 | Received 07 Sep 2020, Accepted 14 Mar 2021, Published online: 02 Apr 2021

References

  • Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863–2869.
  • Greipp PR, San Miguel J, Durie BGM, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23(15):3412–3420.
  • Landgren O, Devlin S, Boulad M, et al. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. Bone Marrow Transplant. 2016;51(12):1565–1568.
  • Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A. 1996;93(11):5512–5516.
  • Mead GP, Carr-Smith HD, Drayson MT, et al. Serum free light chains for monitoring multiple myeloma. Br J Haematol. 2004;126(3):348–354.
  • Gran C, Uttervall K, Borg Bruchfeld J, et al. Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration? Eur J Haematol. 2019;103(6):588–596.
  • Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955–2962.
  • Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e46.
  • Dejoie T, Attal M, Moreau P, et al. Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma. Haematologica. 2016;101(3):356–362.
  • Dimopoulos M, Kyle R, Fermand JP, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011;117(18):4701–4705.
  • Hansen CT, Pedersen PT, Nielsen LC, et al. Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR. Eur J Haematol. 2014;93(5):407–413.
  • Dispenzieri A, Zhang L, Katzmann JA, et al. Appraisal of immunoglobulin free light chain as a marker of response. Blood. 2008;111(10):4908–4915.
  • van Rhee F, Bolejack V, Hollmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007;110(3):827–832.
  • Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715–725.
  • Brioli A, Giles H, Pawlyn C, et al. Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood. 2014;123(22):3414–3419.
  • Markovic U, Leotta V, Tibullo D, et al. Serum free light chains and multiple myeloma: is it time to extend their application? Clin Case Rep. 2020;8(4):617–624.
  • Tacchetti P, Pezzi A, Zamagni E, et al. Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents. Haematologica. 2017;102(3):e104–e107.
  • Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111(2):785–789.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.